Research programme: TLR4/MD-2 complex formation inhibitors - BiolineRx/University of Colorado-BoulderAlternative Names: BL-1110; EDP-34
Latest Information Update: 27 Jun 2014
At a glance
- Originator University of Colorado at Boulder
- Developer BioLineRx; University of Colorado at Boulder
- Class Small molecules
- Mechanism of Action Membrane protein inhibitors; Toll-like receptor 4 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
- Research Scleroderma